Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT)

2016 ◽  
Vol 24 (11) ◽  
pp. 4713-4720 ◽  
Author(s):  
Rehab Chahin ◽  
Husayn Gulamhusein ◽  
Henriette Breunis ◽  
Shabbir M.H. Alibhai
Keyword(s):  
Prostate Cancer ◽  
Quality Of Care ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Treatment Of Osteoporosis ◽  
Prevention And Treatment

Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy

2013 ◽  
Vol 22 (10) ◽  
pp. 2169-2176 ◽  
Author(s):  
Kelly Chipperfield ◽  
Jane Fletcher ◽  
Jeremy Millar ◽  
Joanne Brooker ◽  
Robin Smith ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Predictors Of Depression

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

2010 ◽  
Vol 7 (9) ◽  
pp. 2996-3010 ◽  
Author(s):  
Stacy Elliott ◽  
David M. Latini ◽  
Lauren M. Walker ◽  
Richard Wassersug ◽  
John W. Robinson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Improve Patient

Induced testosterone deficiency: from clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetes

2011 ◽  
Vol 8 (1) ◽  
Author(s):  
George Yu ◽  
Abdulmaged M. Traish
Keyword(s):  
Prostate Cancer ◽  
Insulin Resistance ◽  
Erectile Dysfunction ◽  
Adverse Effects ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
The Past ◽  
Research Findings ◽  
The Relationship

AbstractOver the past 60 years, androgen deprivation therapy has been the mainstay of treatment of metastatic prostate cancer. However, research findings suggest that androgen deprivation therapy inflicts serious adverse effects on overall health and reduces the quality of life. Among the adverse effects known to date are insulin resistance, diabetes, metabolic syndrome fatigue, erectile dysfunction, and cardiovascular disease. In this clinical perspective, we discuss the relationship between induced androgen deficiency and a host of pathologies in the course of treatment with androgen deprivation therapy for prostate cancer patients.

Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer

2017 ◽  
Vol 38 (8) ◽  
pp. 1445-1451 ◽  
Author(s):  
Asli Koskderelioglu ◽  
Muhtesem Gedizlioglu ◽  
Yasin Ceylan ◽  
Bulent Gunlusoy ◽  
Nilden Kahyaoglu
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Quality Of Sleep

scholarly journals Biopsychosocial impact of prostate cancer and androgen-deprivation therapy

2017 ◽  
Vol 11 (10) ◽  
pp. 338-43 ◽  
Author(s):  
Dean A. Tripp ◽  
Phylicia Verreault ◽  
Steven Tong ◽  
Jason Izard ◽  
Angela Black ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Depressive Symptoms ◽  
Androgen Deprivation Therapy ◽  
Watchful Waiting ◽  
Routine Care ◽  
Androgen Deprivation ◽  
Limited Sample ◽  
Adenocarcinoma Of The Prostate ◽  
Localized Disease

Introduction: Prostate cancer is the most non-cutaneous malignancy in men, and androgen-deprivation therapy (ADT) is a cornerstone of management in advanced disease. The aim of this study was to evaluate the association of ADT with changes in depression and mental and physical quality of life (QoL) within a prospective patient cohort design.Methods: Patients were prospectively recruited and consented at a single academic health sciences centre in Ontario, Canada. Inclusion criteria included those men with adenocarcinoma of the prostate and either on watchful waiting or initiating ADT as palliation or as an adjuvant therapy for high-risk localized disease. All three cohorts were followed in routine care and completed psychosocial evaluations, including depression, social support, anxiety, and QoL measures.Results: In comparison to the control cohort of patients with prostate cancer on watchful waiting, initiation of ADT over a two-year period of time was not associated with any changes in depression or mental QoL. Instead, all patients, regardless of treatment cohort, showed increased depression scores and reduced mental QoL scores over time; however, for patients receiving ADT, a significant reduction in physical QoL compared to patients who did not receive ADT was demonstrated.Conclusions: ADT does not appear to significantly impact depressive symptoms and mental QoL over a two-year period; however, the depressive symptoms in this limited sample of men with prostate cancer was higher than expected and monitoring for these may be advisable for those who care for such patients.

Sign in / Sign up

Export Citation Format

Share Document